DRGEM Corp.
KKRX:2636904,905.00
KRW
-145.00
(-2.87%)
ISIN
KR7263690000
Return %
Stock
S&P 500
1Y
-17.01
14.39
3Y
-52.01
81.42
5Y
-59.46
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jung-Byung Park
- Full Time Employees
- 276
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Gwangmyeong-si South Korea
- IPO Date
- Nov 22, 2018
- Website
- drgemhealthcare.com
- Similar Companies
- Business
- DRGEM Corp. is a South Korea-based medical device company that specializes in the research, development, manufacturing, and distribution of diagnostic radiography systems and medical imaging equipment. Founded in 2003 and headquartered in Gwangmyeong-si, South Korea, with manufacturing operations in Gumi-si, the company delivers diagnostic imaging hardware and software solutions to hospitals, diagnostic imaging centers, outpatient clinics, emergency and intensive care facilities, veterinary practices, and global original equipment manufacturer partners across more than 150 countries. The company operates through integrated medical imaging equipment and diagnostic component segments. Its primary product and service offerings comprise stationary digital radiography systems, including the floor-mounted and ceiling-suspended GXR and GXR-SD series; universal U-arm digital X-ray systems, featuring the motorized DIAMOND series with automated positioning and advanced image processing capabilities; motorized and compact mobile digital radiography units designed for bedside, surgical, and emergency point-of-care imaging, including the TOPAZ, RAYMO, and PROMO series; specialized veterinary radiographic systems, including the VXR and VXR-E/EC series; high-frequency X-ray generators and modular sub-assemblies for proprietary systems and OEM integration; digital retrofit upgrade solutions, notably the AcquiDR flat-panel detector conversion package; proprietary medical software suites, including the RADMAX low-dose digital image acquisition and processing platform and GEMPACS picture archiving and communication systems; multi-specialty diagnostic ultrasound systems, including the compact DS20 and cart-based DS30 models; and pre-clinical radiology education tools, including the radiation-free RadTrainer simulation system. In recent developments, DRGEM Corp. has expanded its technological portfolio and market reach through targeted product launches, regulatory clearances, and major international commercial contracts. The company expanded into surgical fluoroscopy with the introduction of PROVUE, an artificial intelligence-driven low-dose mobile C-arm system featuring AI-based real-time denoising algorithms designed to reduce radiation exposure by approximately 70 percent, securing regulatory approval from South Korea's Ministry of Food and Drug Safety. DRGEM strategically diversified its clinical diagnostic portfolio by entering the diagnostic ultrasound market with the commercial rollout of the DS20 and DS30 systems. Within its core digital radiography segment, the company secured United States Food and Drug Administration 510(k) clearances and CE mark certifications for its lightweight RAYMO mobile digital radiography system and PROMO series, alongside the launch of an upgraded motorized auto-stitching stand for long-bone and full-spine examinations. Additionally, the company strengthened its international footprint through significant commercial wins, including a KRW 19.3 billion medical equipment supply contract in Turkey, while continuing to expand its distribution infrastructure across Europe, North America, the Middle East, and the Asia-Pacific region.